Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

BTOG 2018 | Paradigm-changing immunotherapy for advanced NSCLC: the PACIFIC and beyond

Immunotherapy is an exciting area for lung cancer, with numerous possibilities and game-changing potential. Speaking from the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses the future of immunotherapy for non-small cell lung cancer (NSCLC). Prof. Peters highlights the recent Phase III PACIFIC trial (NCT02125461) of durvalumab, which produced outstanding progression-free survival results. She then emphasizes what immunotherapy developments she is most excited about.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.